Algorithm of treatment of patients with pulmonary sarcoidosis
Journal Title: Український терапевтичний журнал - Year 2018, Vol 0, Issue 1
Abstract
Objective — to develop the algorithm of treatment of patients with pulmonary sarcoidosis, based on the data regarding the rate of contraindications, adverse reactions and resistance to glucocorticosteroids (GCS) and the choice of the optimal drug for immunosuppressive therapy. Materials and methods. The study involved 185 patients with newly diagnosed lung parenchyma sarcoidosis to investigate the rate of contraindications, adverse reactions and resistance to GCS was conducted. The comparative study of azathioprine, leflunomide and methotrexate efficacy was performed in 43 pulmonary sarcoidosis patients. Results and discussion. At average, every eighth patient with stage II—III pulmonary sarcoidosis (12.4 %) required the administration of immunosuppressive therapy immediately after the diagnosis established due to contraindications for GCS use. During the course of GCS treatment, the necessity to use immunosuppressive drugs increases due to development of serious side effects or resistance in up to 32.4 % of patients. That is, every third patient in different phases of treatment would require immunosuppressant drugs. In majority of patients with GSC contraindications/serious side effects, an alternative therapy with azathioprine 50 mg/day with subsequent elevation of daily dose on 25 mg/day every 2 weeks (until maximum dose reached) was not effective. The use of leflunomide (20 mg/day) increased the rate of regression of sarcoidosis after 3 months of the therapy by 50 %. Unlike azathioprine and leflunomide, methotrexate (10 mg/week) was effective in the most part of patients (73,7 %). Methotrexate had more favorable safety profile. In comparison with azathioprine and leflunomide there were no serious side effects registered during 3 months of therapy with methotrexate (10 mg/week). Conclusions. An algorithm of therapy of patients with sarcoidosis has been created, based on the taking into account the contraindications, adverse reactions and resistance to GCS and the use of methotrexate as immunosuppressive medication with optimal efficacy and safety properties.
Authors and Affiliations
V. K. Gavrysyuk, E. О. Merenkova, G. L. Gumeniuk, O. V. Bychenko
Keywords
Related Articles
- EP ID EP276354
- DOI -
- Views 163
- Downloads 0
Interrelation of cognitive impairments and structural and functional features of the left ventricle of the heart in patients with hypertension
Objective — to study morphofunctional changes in the left ventricle in patients with arterial hypertension with cognitive impairment. Materials and methods. Examinations involved 76 patients with stage II arterial hypert...
The relationship between prolactin levels, sleep disorders and the effectiveness of glycaemia correction in patients with hypertension and type 2 diabetes mellitus
Objective — to assess sleep disorders in patients with hypertension and type 2 diabetes mellitus and to establish the role of prolactin in the formation of these changes. Materials and methods. The study included 63 pati...
Polymorphous variants А1166C of АТІІR1 gene in patients with cardiovascular pathology
The review presents analysis of the role of the polymorphic variant of gene of type 1 receptors to the angiotensin II (A1166C polymorphism of ATIIR1 gene) in the arterial hypertension, heart failure, myocardial infarctio...
Influence of hypothyroidism on the level of 8-hydroxy-2’-deoxyguanosine as a biomarker of oxidative damage in comorbid conditions
Objective — to evaluate the hypothyroidism effects on the level of 8-hydroxy-2’-deoxyguanosine (8-OHdG) as a biomarker of oxidative damage in the comorbid course of hypertension (H), type 2 diabetes mellitus (DM2T) and s...
Gender differences in the effects of renin-angiotensin system inhibitors and calcium channel blockers in combination therapy with diuretics on indicators of arterial hemodynamics, vascular stiffness and structural and functional state of the heart
Objective — to compare the gender-associated effects of 6-month (М6) treatment of patients aged < 65 years with arterial hypertension (AH) 1—2 degree using angiotensin-converting enzyme inhibitor (ACE inhibitor) or angio...